CGTX — Cognition Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $27.63m
- $2.62m
Annual income statement for Cognition Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.5 | 28.2 | 43.6 | 50.7 | 54 |
| Operating Profit | -17.5 | -28.2 | -43.6 | -50.7 | -54 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.84 | -11.7 | -21.4 | -25.8 | -34 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.84 | -11.7 | -21.4 | -25.8 | -34 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.84 | -11.7 | -21.4 | -25.8 | -34 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.1 | -16.2 | -21.4 | -25.8 | -34 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.57 | -0.739 | -0.905 | -0.859 | -0.855 |
| Dividends per Share |